Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02927210 · ClinicalTrials.gov registry record · Phase 1
Injectable DMAU for Male Contraception in Healthy Male Volunteers (CCN015)
A Phase 1 study, sponsored by Kimberly Myer.
- Completed
- Registry status
- Phase 1
- Development phase
- 106
- Enrollment target
NCT02927210 is a Phase 1 study that has completed, run by Kimberly Myer. The registered enrollment target is 106 participants.
The verdict
NCT02927210, a Phase 1 study, has completed, sponsored by Kimberly Myer.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 106 participants
- Enrollment target
Study Summary
This is a Phase I multicenter, double-blind, single dose, dose-ranging study, in healthy men to evaluate the safety and tolerability, pharmacokinetics and pharmacodynamics of Dimethandrolone Undecanoate (DMAU) administered as an intramuscular or subcutaneous injection.
Interventions
- DRUG Placebo
- DRUG Dimethandrolone Undecanoate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 106 participants |
| Start Date | 2017-02-15 |
| Est. Completion | 2025-04-29 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02927210
The ClinicalTrials.gov registry entry for NCT02927210 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 106 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Kimberly Myer, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02927210 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02927210 about?
NCT02927210 is a clinical study titled "Injectable DMAU for Male Contraception in Healthy Male Volunteers (CCN015)". This is a Phase I multicenter, double-blind, single dose, dose-ranging study, in healthy men to evaluate the safety and tolerability, pharmacokinetics and pharmacodynamics of Dimethandrolone Undecanoate (DMAU) administered as an intramuscular or subcutaneous injection.
What is the current status of trial NCT02927210?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 106 participants. The study started on 2017-02-15. Estimated completion is 2025-04-29.
What interventions are being tested in trial NCT02927210?
The interventions under investigation include: Placebo (DRUG), Dimethandrolone Undecanoate (DRUG).
Who is sponsoring clinical trial NCT02927210?
This trial is sponsored by Kimberly Myer, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.